Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 67 |
| Active Pipeline (Recruiting Now) | 22 (8) |
| Completed vs Stopped Early | 32 / 7 (10.4%) |
| Median Closed Actual Enrollment | 86 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University Hospital Southampton NHS Foundation Trust | Southampton, Hampshire | 5 |
| John Radcliffe Hospital | Oxford | 5 |
| Imperial College Healthcare NHS Trust | London | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04400838 | Investigating a Vaccine Against COVID-19 | Phase II/III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the University of Oxford Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.